In recent years, the field of toxinology has expanded substantially. On the one hand it studies venomous animals, plants and microorganisms in detail to understand their mode of action on targets. While on the other, it explores the biochemical composition, genomics and proteomics of toxins and venoms to understand their interaction with life forms (especially humans), development of antidotes and exploring their pharmacological potential. Therefore, toxinology has deep linkages with biochemistry, molecular biology, anatomy and pharmacology. In addition, there is a fastdeveloping applied subfield, clinical toxinology, which deals with understanding and managing medical effects of toxins on human body. Given the huge impact of toxinbased deaths globally, and the potential of venom in generation of drugs for so-far incurable diseases (for example, diabetes, chronic pain), the continued research and growth of the field is imminent. This has led to the growth of research in the area and the consequent scholarly output by way of publications in journals and books. Despite this ever-growing body of literature within biomedical sciences, there is still no all-inclusive reference work available that collects all of the important biochemical, biomedical and clinical insights relating to toxinology. Composed of 12 volumes, Toxinology provides comprehensive and authoritative coverage of the main areas in toxinology, from fundamental concepts to new developments and applications in the field. Each volume comprises a focused and carefully chosen collection of contributions from leading names in the subject.
Preface
The term TOXIN is derived from the Greek word Toeikov and is defined as a substance derived from tissues of a plant, animal, or microorganism that has a deleterious effect on other living organisms. Studying their detailed structure, function, and mechanism of action as well as finding an antidote to these toxins is the field of TOXINOLOGY, and the scientists are called TOXINOLOGISTS.
In recent years, the field of toxinology has expanded substantially. On the one hand, it studies venomous animals, plants, and microorganisms in detail to understand their habitat, distribution, identification, as well as mode of action on targets, while on the other, it explores the biochemical composition, genomics, and proteomics of toxins and venoms to understand their interaction with life forms (especially humans), the development of antidotes, and their pharmacological potential for drug discovery. Therefore, toxinology has deep linkages with biochemistry, molecular biology, anatomy, pharmacology, etc. In addition, there is a fast developing applied subfield, clinical toxinology, which deals with understanding and managing medical effects of venoms and toxins on the human body following envenomations. Given the huge impact of envenomation-based deaths globally and the potential of venom in the generation of drugs for debilitating diseases (e.g., diabetes, chronic pain, and cancer), the continued research and growth of the field is imminent.
Springer has taken the bold initiative of producing this series, which is not an easy target of producing about 12 volumes, namely, biological toxins and bioterrorism, clinical toxinology, scorpion venoms, spider venoms, snake venoms, marine and freshwater toxins, toxins and drug discovery, venom genomics and proteomics, evolution of venomous animals and their toxins, plant toxins, and microbial toxins.
This volume deals mainly with the specialized aspect of toxins and drug discovery. Man has been using natural resources especially plants to treat diseases from very early times in history of mankind. Although many drugs derived from plants and microbes have been discovered and being used in clinical practice, not many drugs have been developed from venoms and toxins although many laboratories v worldwide are actively working on it. This volume describe some of the recent developments in this research area, such as snake venoms, conotoxins, bioinformatics in drug discovery from peptide toxins. Professor Luo discovered six new Hainan conotoxins that target nicotinic acetylcholine receptor (nAChR) subtypes, including atypical α-conotoxin LtIA that targets a novel microsite of the α3β2 nAChR, α-conotoxin TxIB that selectively targets α6/ α3β2β3 nAChR, α4/7-conotoxin LvIA that selectively blocks α3β2 vs. α6/α3β2β3, α-conotoxin TxID that potently blocks rat α3β4 nAChR, a novel inhibitor of α9α10 nAChR that delineates a new conotoxin superfamily, and an αO-conotoxin GeXIVA which is a potent α9α10 nAChR antagonist with antihypersensitive effect of neuropathic pain. Structure and function characterization of more Hainan conopeptides is ongoing continuously. The nAChRs are potential targets for the treatment of various neuropsychiatric diseases, including pain, cancer, addiction, epilepsy, Alzheimer's disease, Parkinson's disease, schizophrenia, etc. These Hainan conotoxins show great potential in medical applications.
